发明申请
US20150366835A1 Methods of Subtyping CRC and their Association with Treatment of Colon Cancer Patients with Oxaliplatin
审中-公开
方法分析CRC及其与治疗结肠癌患者与奥沙利铂的关系
- 专利标题： Methods of Subtyping CRC and their Association with Treatment of Colon Cancer Patients with Oxaliplatin
- 专利标题（中）： 方法分析CRC及其与治疗结肠癌患者与奥沙利铂的关系
-
申请号： US14738757申请日： 2015-06-12
-
公开(公告)号： US20150366835A1公开(公告)日： 2015-12-24
- 发明人: Katherine Lea Pogue-Geile , Nan Song , Soonmyung Paik
- 申请人： NSABP Foundation, Inc.
- 主分类号： A61K31/282
- IPC分类号： A61K31/282 ; C12Q1/68
摘要：
A gene expression signature identifies stage II colon cancer patients who will receive benefit from oxaliplatin. Oxaliplatin has been shown to lengthen the survival of colon cancer patients, when it is combined with 5-fluorouracil plus leucovorin (FULV) in NSABP clinical trial C-07. Gene expression signatures are used first to classify tumors with regard to their respective subtypes, enterocyte, TA, goblet, inflammatory and stem-like and detection of expression of the enterocyte subtype directs treatment of the patient with oxaliplatin.
公开/授权文献
信息查询
